Ganga Pharmaceuticals (539680) H2 23/24 earnings summary

Executive summary

• Revenue for FY 2023-24 was ₹297.53 lakh, up from ₹288.45 lakh in FY 2022-23, with net profit rising to ₹4.66 lakh from ₹3.93 lakh year-over-year.

• The company issued 7,75,000 equity shares at a premium and 17,75,000 share warrants via preferential issue, increasing paid-up capital to ₹4.84 crore.

• No dividend was recommended for FY 2023-24; no material changes or significant legal orders impacted the company post year-end.

Financial highlights

• Total income for FY 2023-24: ₹297.53 lakh; total expenses: ₹291.20 lakh; profit before tax: ₹6.33 lakh.

• Net profit after tax for FY 2023-24: ₹4.66 lakh, up from ₹3.93 lakh in FY 2022-23.

• Earnings per share (EPS) for FY 2023-24: ₹0.11 basic, ₹0.07 diluted (previous year: ₹0.10 each).

• Market capitalization as of March 31, 2024: ₹11.80 crore; price-earnings ratio: 0.11.

• No pending litigation, no long-term contracts with foreseeable losses, and no defaults on borrowings.

Outlook and guidance

• The company expects healthy growth in the Ayurveda industry, driven by rising demand for natural products and government support.

• Plans to invest in manufacturing and marketing to strengthen brand awareness and capture new markets.